These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 26032442)
21. Is it time to change the gold standard of obsessive-compulsive disorder severity assessment? Factor structure of the Yale-Brown Obsessive-Compulsive Scale. Fatori D; Costa DL; Asbahr FR; Ferrão YA; Rosário MC; Miguel EC; Shavitt RG; Batistuzzo MC Aust N Z J Psychiatry; 2020 Jul; 54(7):732-742. PubMed ID: 32475123 [TBL] [Abstract][Full Text] [Related]
22. [Validation of the French version of the Binge Eating Scale: Examination of its factor structure, internal consistency and construct validity in a non-clinical and a clinical population]. Brunault P; Gaillard P; Ballon N; Couet C; Isnard P; Cook S; Delbachian I; Réveillère C; Courtois R Encephale; 2016 Oct; 42(5):426-433. PubMed ID: 27017318 [TBL] [Abstract][Full Text] [Related]
23. Development of a chinese version of the Yale-Brown obsessive compulsive scale for heavy drinking. Gau SS; Liu CY; Lee CS; Chang JC; Chang CJ; Li CF; Chen CC; Cheng AT Alcohol Clin Exp Res; 2005 Jul; 29(7):1172-9. PubMed ID: 16046872 [TBL] [Abstract][Full Text] [Related]
25. Comparisons among the Yale-Brown Obsessive-Compulsive Scale, compulsion checklist, and other measures of obsessive-compulsive disorder. Nakagawa A; Marks IM; Takei N; De Araujo LA; Ito LM Br J Psychiatry; 1996 Jul; 169(1):108-12. PubMed ID: 8818378 [TBL] [Abstract][Full Text] [Related]
26. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Placebo-Controlled, Flexible-Dose Clinical Trial. McElroy SL; Hudson JI; Grilo CM; Guerdjikova AI; Deng L; Koblan KS; Goldman R; Navia B; Hopkins S; Loebel A J Clin Psychiatry; 2020 Sep; 81(5):. PubMed ID: 32926604 [TBL] [Abstract][Full Text] [Related]
28. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Phillips KA; Hollander E; Rasmussen SA; Aronowitz BR; DeCaria C; Goodman WK Psychopharmacol Bull; 1997; 33(1):17-22. PubMed ID: 9133747 [TBL] [Abstract][Full Text] [Related]
29. The Toronto Obsessive-Compulsive Scale: Psychometrics of a Dimensional Measure of Obsessive-Compulsive Traits. Park LS; Burton CL; Dupuis A; Shan J; Storch EA; Crosbie J; Schachar RJ; Arnold PD J Am Acad Child Adolesc Psychiatry; 2016 Apr; 55(4):310-318.e4. PubMed ID: 27015722 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Yale-Brown Obsessive Compulsive Scale (YBOCS-hd) for heavy drinking with mild to moderately dependent alcohol abusers. Fedoroff I; Sobell LC; Agrawal S; Sobell MB; Gavin DR Alcohol Clin Exp Res; 1999 Sep; 23(9):1477-83. PubMed ID: 10512313 [TBL] [Abstract][Full Text] [Related]
31. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. Kornstein SG; Bliss C; Kando J; Madhoo M J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099 [TBL] [Abstract][Full Text] [Related]
32. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale. Woody SR; Steketee G; Chambless DL Behav Res Ther; 1995 Jun; 33(5):597-605. PubMed ID: 7598684 [TBL] [Abstract][Full Text] [Related]
33. Development and initial validation of the obsessive compulsive eating scale. Niemiec MA; Boswell JF; Hormes JM Obesity (Silver Spring); 2016 Aug; 24(8):1803-9. PubMed ID: 27296154 [TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial. McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285 [TBL] [Abstract][Full Text] [Related]
35. Assessment of food addiction using the Yale Food Addiction Scale 2.0 in individuals with binge-eating disorder symptomatology: Factor structure, psychometric properties, and clinical significance. Linardon J; Messer M Psychiatry Res; 2019 Sep; 279():216-221. PubMed ID: 30862369 [TBL] [Abstract][Full Text] [Related]
36. Placebo effect after prefrontal magnetic stimulation in the treatment of resistant obsessive-compulsive disorder: a randomized controlled trial. Mansur CG; Myczkowki ML; de Barros Cabral S; Sartorelli Mdo C; Bellini BB; Dias AM; Bernik MA; Marcolin MA Int J Neuropsychopharmacol; 2011 Nov; 14(10):1389-97. PubMed ID: 21557884 [TBL] [Abstract][Full Text] [Related]
37. [Dimensional Approach to Obsessive-Compulsive Disorder: Dimensional Obsessive-Compulsive Scale with Turkish Psychometric Properties]. Şafak Y; Say Öcal D; Özdel K; Kuru E; Örsel S Turk Psikiyatri Derg; 2018; 29(2):122-130. PubMed ID: 30215841 [TBL] [Abstract][Full Text] [Related]
38. Initial data on a 5-item measure of OCD symptom severity and change: The obsessive compulsive session change index (OCSCI). Collins LM; Coles ME J Anxiety Disord; 2016 Oct; 43():8-13. PubMed ID: 27467028 [TBL] [Abstract][Full Text] [Related]
39. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder. Costa DLDC; Barbosa VS; Requena G; Shavitt RG; Pereira CAB; Diniz JB J Psychopharmacol; 2017 Oct; 31(10):1312-1322. PubMed ID: 28441896 [TBL] [Abstract][Full Text] [Related]